Ollin Biosciences
“Ollin Biosciences, a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, announced an oversubscribed $330 million Series B financing.”
“In a market where many rounds are quietly structured, Ollin Biosciences calling out an oversubscribed round is a deliberate signal of demand exceeding supply.”
“Ollin Biosciences...$330M Series B for antibody drugs targeting macular degeneration and diabetic macular edema”
“Vision disease-focused Ollin Biosciences secured a $330 million Series B.”
Source→“Vision disease-focused Ollin Biosciences secured a $330 million Series B led by TCGX and Arch Venture Partners.”
Source→“Ollin Biosciences raised $330M Series B led by TCGX and Arch Venture Partners, joined by a16z and Blackstone”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.